VM-26 as a second drug in the treatment of brain gliomas

A. Kessinger, H. M. Lemon, J. F. Foley

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Twenty patients previously treated with surgical resection, radiation therapy, and a nitrosourea for malignant gliomas of the brain were given VM-26 as a second chemotherapeutic agent when evidence of tumor progression occurred. Thirty-five percent achieved an arrest or decrease of neurologic symptoms, with a median length of response (arrest and tumor regression) of 22 weeks.

Original languageEnglish (US)
Pages (from-to)511-512
Number of pages2
JournalCancer treatment reports
Issue number3
StatePublished - 1979
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'VM-26 as a second drug in the treatment of brain gliomas'. Together they form a unique fingerprint.

Cite this